Video

Dr. Patel on Choosing a Chemoimmunotherapy Treatment in NSCLC

Manish Patel, MD, DO, discusses choosing a chemoimmunotherapy regimen for patients with advanced, metastatic non–small cell lung cancer.

Manish Patel, MD, DO, hematologist, oncologist, associate professor of medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, discusses choosing a chemoimmunotherapy regimen for patients with advanced, metastatic non–small cell lung cancer (NSCLC).

The phase 3 CheckMate 9LA trial (NCT03215706) evaluates chemotherapy plus nivolumab (Opdivo) and ipilimumab (Yervoy), providing patients with an alternative to pembrolizumab (Keytruda) plus chemotherapy, Patel says. Current data for each regimen suggest that there are similar efficacy outcomes and toxicity profiles for each of these regimens, Patel adds. However, the absence of head-to-head comparative studies makes the decision challenging, Patel continues.

Treatment selection should account for both updated efficacy results and individual patient factors, Patel continues. For example, patients who are reluctant to undergo chemotherapy may benefit more from the CheckMate 9LA regimen, Patel says. Alternatively, the known reliability and efficacy of pembrolizumab plus chemotherapy continue to support its use as a standard-of-care regimen, Patel notes.

Ultimately, both regimens are viable treatment options for patients with NSCLC, Patel concludes.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center